Jasper Therapeutics Inc Cash Flow-to-Debt Ratio
Jasper Therapeutics Inc cash flow-to-debt ratio. Jasper Therapeutics Inc (JSPR) has a Cash Flow-to-Debt Ratio of -0.67x as of June 2026, meaning its operating cash flow of $-6.92 Million could theoretically repay -1% of its total liabilities ($10.39 Million) in one year. Check JSPR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jasper Therapeutics Inc (2019–2025)
Cash flow-to-debt ratio of Jasper Therapeutics Inc from 2019 to 2025. Historical debt coverage capacity for Jasper Therapeutics Inc across 7 annual periods. Also explore net asset momentum of Jasper Therapeutics Inc to track the company's year-over-year net asset growth rate.
Jasper Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Jasper Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Jasper Therapeutics Inc. For the full cash flow conversion analysis, see Jasper Therapeutics Inc (JSPR) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.44x | $-77.16 Million | $31.63 Million | ▲ +29.0% |
| 2024 | -3.43x | $-62.60 Million | $18.23 Million | ▼ -8.5% |
| 2023 | -3.16x | $-52.07 Million | $16.45 Million | ▲ +14.6% |
| 2022 | -3.71x | $-45.86 Million | $12.37 Million | ▼ -165.6% |
| 2021 | -1.40x | $-33.68 Million | $24.14 Million | ▼ -346.8% |
| 2020 | -0.31x | $-18.27 Million | $58.49 Million | ▲ +3.1% |
| 2019 | -0.32x | $-1.97 Million | $6.11 Million | — |